CAR-T in B-cell lymphomas: the past, present and future

The advent of chimeric antigen receptor T-cell therapy (CAR-T) is a historic landmark in the treatment of B-cell lymphoid malignancies considering its proven efficacy in the salvage setting for patients with limited effective therapeutic options. CAR-T cell therapy is also the first gene therapy to be approved by the US Food and Drug Administration (FDA) for clinical use, initially in B-cell acute lymphocytic leukemia and then shortly after in aggressive mature B-cell lymphomas1. In the case of aggressive mature B-cell lymphomas before CAR-T era, the retrospective international SCHOLAR-1 study demonstrated that the median overall survival in patients with refractory or relapsed diffuse large B-cell lymphoma was approximately 6 months, with only 20% of patients being alive at 2 years2.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research